Table 2.

Analysis of serum from 30 patients before and up to 2 weeks after evacuation of a complete hydatidiform mole (hCG >500 IU/L total).1

Total hCG concentration,2 IU/LDilution supplied to test centersCommercial hCGβ RIA, IU/LBeckman Access hCGβ, IU/LAbbott AxSYM hCGβ, IU/LChiron ACS:180 hCGβ, IU/LDPC Immulite hCG, IU/LBaxter Stratus hCG, IU/LSerono MAIAclone, IU/L
560511212312112111291112
7401074848186736980
76010769711190836675
78010789272100777686
8001080937094756780
10205204220197223206179220
121010121137134147110108121
142010142162157150130100128
180010180209184218174159187
27003090112101115867685
363030121128124137108105122
393030131142146154125102122
425010425284353245219130171
456060769983100838291
534030178176164191149150175
56406094110981159093105
6120601021071141119690103
681030227245236245214181222
690060115137119152108105123
810030270279245283241237264
825015055514559594853
10 56060176203165214167164179
12 7501508510688142948899
14 70015098132110162110105122
16 200150108139114178119110121
23 850150159174154213140133144
25 000100025413650353335
27 150150181262239284220201225
44 000400110129115162107103121
54 400400136174163209143146168
Median result114134120151110104122
Total number varying >25% from RIA result2 of 300 of 306 of 301 of 302 of 301 of 30
  • 1 Samples were tested for hCG in a RIA, and results were compared with those for 6 immunometric assays. Samples were diluted to 200 IU/L based on the Charing Cross house immunoassay, coded, and tested blindly by multiple external laboratories as described in Materials and Methods. Results varying >25% from commercial hCGβ RIA values are indicated in bold.

  • 2 As determined from dilution and commercial hCGβ RIA.